Update on new drug supply bill - advanced therapies financing


The "better safety in drug supply" bill (GSAV) will be adopted before this year's parliamentary summer recess - and it will bring some revisions for advanced therapies. Experts from G-BA and umbrella payer group GKV-Spitzenverband as well as a member of Parliament will review the changes for reimbursement and collection of post-launch data.

Berlin, Germany

More information

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.